Setting the price abtaining market access for a new pharmaceutical remains one of the biggest commer...
Read moreBiosimilars are becoming more widely available across Europe, with many payers at each level involve...
Read moreThe aim of this study is to compare the key aspects companies must consider when seeking HTA scienti...
Read moreUnderstanding payer value and evidence requirements to secure pricing and reimbursement for a novel ...
Read moreThe European Commission (EC) has recently set out its draft proposal for adopting an EU-wide health...
Read moreIn June 2018, Remap Consulting had the pleasure of attending the annual National Institute of Health...
Read moreThe aim of this study was to determine the impact of delivery device reducing drug wastage.
Read moreDevelopment and implementation of the optimum price submission strategy for a product in the EU.
Read moreHistorically, patient involvement in health technology assessment processes and decision-making has ...
Read moreOver the last year, the European Commission (EC) has been consulting on multiple scenarios for HTA h...
Read more